Post Hoc Secondary Analysis of RCT: Rivaroxaban monotherapy is associated with better outcomes vs. combination therapy with antiplatelets in patients with atrial fibrillation and stable coronary artery disease.
17 Jun, 2022 | 11:07h | UTCRivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial – JAMA Cardiology (free for a limited period)
Commentaries:
Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease: Does Less Mean More? – JAMA Cardiology (free for a limited period)
Rivaroxaban Monotherapy Linked to Lower Event Risk in Patients with AF, Stable CAD – HCPLive
Commentary on Twitter
In this post-hoc study of the AFIRE RCT, recurrent event analyses showed that rivaroxaban monotherapy was associated with lower risks of total thrombotic and/or bleeding events than rivaroxaban plus antiplatelet therapy in patients with AF and stable CAD. https://t.co/TGwatvlrKR
— JAMA Cardiology (@JAMACardio) June 15, 2022